Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: clutterer who wrote (23227)	1/28/1999 10:38:00 AM
From: Jenna	Respond to of 120523

OTEXF..another earnings play to consider: SFSK very promising still not in..

To: clutterer who wrote (23227)	1/28/1999 12:33:00 PM
From: Henry Niman	Respond to of 120523

LGND has been getting quite a bit of press lately. They've been mentioned on CNBC several times this year by David Molowa of Bear Stearns, Jim McCamant of Medical Technology Stock Letter, and Michael Murphy of California Technology Stock Letter. Kiplinger's cover story this month is on "Medical Miricles: kiplinger.com and LGND is one of the 5 Biotechs mentioned (and in the associated chat room, the author of the review admitted that LGND was his favorite). Last week Michael Murphy indicated that FDA approval would be within 2 weeks, and yesterday, TokyoMex, put LGND on his BUY list (and LGND also seems to be on wallstwatch's rumor list because of the anticipated FDA approval).